ORBIS receive $5 million from AIG

Article

ORBIS International has been awarded a $5,000,000 grant from American International Group (AIG) to ensure the growth of its long-term blindness prevention programmes in the developing world.

ORBIS International has been awarded a $5,000,000 grant from American International Group (AIG) to ensure the growth of its long-term blindness prevention programmes in the developing world.

Initially the grant will be devoted to combating blindness in China, India and Vietnam by providing sustainable eye care services. Projects will focus on the practical, systemic challenges facing service providers, such as improving rural services in Vietnam, developing paediatric ophthalmology centres in India and sustaining affordable rural eye care services in western China.

By awarding this money, AIG joins founding members Alcon and FedEx in the ORBIS Alliance for Sight and is designated a Global Sponsor.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.